Bringing Immuno-Oncology into Focus
Advanta IO Gene Expression Assay and Workflow
Tumor gene expression has proven to be an effective measure of immune response in cancer progression and therapeutic response research. As emerging therapies reveal new biomarkers and expand the need for samples, the costs and labor required to complete this important work also rise. Cancer researchers now have a reliable, sensitive and cost-effective toolset for identifying gene expression signatures from immune and cancer cells: the Advanta™ IO Gene Expression Assay, used with the Biomark™ HD system.
A powerful immuno-oncology focused assay
The Advanta IO Gene Expression Assay was developed in collaboration with leading researchers in the biopharmaceutical industry to provide the right balance of biomarker breadth, assay flexibility and workflow efficiency.
The panel consists of 170 genes, including 91 reported in Nature, where Roy Herbst et al. defined a gene set representing tumor and immune response. The panel includes markers for:
- Immune cell identification
- Immune and cancer cell function
- Immune regulation and cell fate
- Checkpoint therapy response
Optimized for FFPE and fresh frozen tumor samples, the Advanta IO Gene Expression Assay uses TaqMan® chemistry to sensitively measure gene expression, with five reference genes serving as analysis controls. Combined with Fluidigm microfluidics technology, the assay uniquely offers significant workflow efficiencies over traditional gene expression profiling methods. Each reaction is miniaturized to nanoliter volume and controlled using precise automation to empower accurate and cost-effective qPCR analysis across a large dynamic range. Since assay introduction into the integrated fluidic circuit (IFC) is under user control, researchers also have the flexibility to add up to 17 new assays or exchange gene assays within the panel to achieve experimental goals—all without affecting the original panel content, protocol or workflow.
Download the flyer to learn more about the Advanta IO Gene Expression Assay workflow using the Biomark HD system, and to see the list of gene expression targets covered in the assay.
Sample case study
In a 2016 paper published by The Lancet for the POPLAR study, “Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer,” Louis Fehrenbacher et al. used immunohistochemistry, and also ran a gene expression panel of 91 genes featured in the Herbst paper. These genes are included in the Advanta IO Gene Expression Assay.
The team subsequently used these research results to develop a gene signature based on a subset of the panel, that provided data that could potentially be used for developing future diagnostics tests.
Yongpan Yan, PhD
Febe van Maldegem, PhD, and Karishma Valand
Melissa Davis, PhD
Rebecca Ihrie, PhD
Bernd Bodenmiller, PhD
David L. Rimm, MD, PhD
Sonia Gavasso, PhD
Sean Bendall, PhD
Ansuman Satpathy, MD, PhD
Evan Newell, PhD
Akil Merchant, MD
Wendy Fantl, PhD
Corinne Ramos, PhD, MBA
Shyam Prabhakar, PhD
Dr. Dexi Chen, PhD, MD
Scott Magness, PhD
Dr. Luc Teyton, MD, PhD
Jo Vandesompele, PhD
Christophe Lancrin, PhD
Shyam Prabhakar, PhD
Simone Mayer, PhD
Kelly Nudelman, PhD
Jonathan M. Irish, PhD
Scientist Michael Stubbington, PhD
Learn more about how our customers are leveraging Fluidigm technologyVIEW ALL
Unless explicitly and expressly stated otherwise, all Fluidigm products are provided for Research Use Only, not for use in diagnostic procedures. For more information see www.fluidigm.com/legal/notices